Oxagen Subscribes To Celera's Genomic Databases
Rockville, MD and Abingdon, UK - January 18, 2002
Celera Genomics (NYSE:CRA), an Applera Corporation business, announced today that Oxagen Limited, the privately held genomics company based in Abingdon, UK, signed a multi-year subscription agreement to Celera's proprietary genomic databases. Financial terms of the agreement were not disclosed.
“The Celera Discovery System offers researchers a comprehensive platform from which to launch and customize their discovery efforts,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “We are pleased that Oxagen has chosen to access our accurate databases and utilize our bioinformatics infrastructure and data-mining tools as we believe CDS will enable their researchers to advance their genomics-based drug discovery research programs.”
“Oxagen has built up extensive family collections covering a number of common human diseases. We have identified many novel linkage regions from our analysis of these collections. This agreement to access Celera’s high quality human and mouse sequence data plus the SNP database should greatly accelerate our progress in identifying disease genes and drug targets,” said Trevor Nicholls, Ph.D., chief executive officer of Oxagen.
Oxagen has rapidly established itself as a leading player in the study of complex disease genetics, conducting programs in cardiovascular disease, inflammatory disease and metabolic and endocrine disorders. Oxagen aims to identify new therapeutics and diagnostics by capitalizing on insights from genetics and specializes in using large-scale family studies to understand the association of genes and genetic variations with disease. The Company believes that this approach is the most effective way to provide fundamental insights into the molecular mechanisms of disease. In addition to furthering the discovery of disease-related genes, Oxagen’s database of clinical cases and controls and its increasing collection of validated candidate genes offers a valuable resource to other life sciences companies wishing to understand the impact of genetic variation on the discovery, development and marketing of therapeutics throughout the product cycle. Oxagen has formed collaborations with more than 30 leading clinical research groups in the UK, continental Europe and worldwide. Oxagen is running gene discovery programmes in the areas of cardiovascular disease (in partnership with AstraZeneca), inflammation (asthma, inflammatory bowel disease and psoriasis) and metabolic and endocrine disorders (osteoporosis, endometriosis, polycystic ovary syndrome and auto-immune thyroid disease). The Company has established extensive databases of phenotype and genotype records in these diseases which, combined with the growing list of candidate genes and proprietary intellectual property arising from the analysis of the samples, offer numerous partnering opportunities for companies seeking novel target discovery programs and pharmacogenomic validation.
Oxagen was established in April 1997, initially funded by the Wellcome Trust, Oxford University and private investors 3i Group plc and Advent Funds. In December 2000 the Company completed a significant private financing round, raising £30m net through the issue of new convertible preference shares.
The Company has established an extensive technical and analytical capability and has some 110 members of staff all based in purpose-built facilities in Milton Park, south of Oxford. For more information on Oxagen please see our website at http://www.oxagen.co.uk
About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com. Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) expected operating losses; (2) dependence on the continued assembly and annotation of the human and other genomes; (3) unproven use of genomics information to develop or commercialize products; (4) dependence on the unique expertise of its scientific and management staff; (5) dependence on computer hardware, software, and Internet applications; (6) potential adverse effect on Celera Genomics’ intellectual property protection and the value of its products and services due to public disclosure of genomics sequence data; (7) potential for government regulation of Celera Genomics’ or its customers’ products and services; and (8) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.